Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review

Abstract Background Selective RET inhibitors have been approved by the Chinese government for the treatment of RET-rearranged non-small cell lung cancer. This study aimed to illustrate the efficacy and safety of selective RET inhibitors in a real-world clinical context in China. Methods Patients wit...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Siyu Lei, Linyan Tian, Lu Yang, Yaning Yang, Junling Li, Xingsheng Hu, Xuezhi Hao, Haiyan Xu, Yan Wang
Format:	Article
Language:	English
Published:	BMC 2024-11-01
Subjects:	Non-small cell lung cancer RET rearrangement RET-TKI Real-world study
Online Access:	https://doi.org/10.1186/s12885-024-13155-z